ASH’s new targets, Avistone emerges and the latest from Washington

Plus the TIGIT landscape and leadership at NIH, FDA

On the latest BioCentury This Week podcast, BioCentury’s editors assess the new targets emerging at this year’s American Society of Hematology (ASH) annual meeting. Senior Editor Lauren Martz discusses how innovation in targets for hematological malignancies could be shifting from B cell lymphomas to T cell cancers.

Martz and Editor in Chief Simone Fishburn deliver their takeaways on the state of the TIGIT landscape following Genentech Inc.’s tiragolumab data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, and Washington Editor Steve Usdin brings the latest updates on the search for a new NIH chief and the upcoming nomination hearing for Robert Califf as FDA commissioner.

In this week’s Emerging Company Spotlight, BioCentury This Week Host Jeff Cranmer highlights Avistone Pharmaceuticals. The company debuted last week with one of China biotech’s largest series A rounds at $200 million, and a global vision to deliver best- and first-in-class therapies to patients in China and beyond, starting with APL-001, a small molecule c-MET inhibitor licensed from Crown Biosciences International Inc. spinout Apollomics Inc.